#United States #Los Angeles #Cyrano Therapeutics #CYR-064 #Phase 2 Trial

Cyrano Therapeutics Unveils Promising Results for Smell Loss Treatment from Phase 2 Study

Cyrano Therapeutics, Inc., a pioneering company in the field of regenerative medicine, recently presented remarkable data from its Phase 2 FLAVOR clinical trial, conducted to evaluate its investigational drug CYR-064. This novel treatment targets persistent smell loss, known medically as hyposmia, often following viral infections. The findings were disclosed at the 72nd Annual Meeting of the American Rhinologic Society (ARS) in Los Angeles, California, where it received a distinguished slot in the